The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels

Abstract

The solid organ transplant community is slow to adopt the routine practice of using direct oral anticoagulants. Rivaroxaban and apixaban share common metabolic pathways with tacrolimus. This study aimed to clarify the impact of rivaroxaban/apixaban on tacrolimus troughs. Fifty solid organ transplant recipients with concomitant use of tacrolimus and rivaroxaban/apixaban were retrospectively assessed for changes in tacrolimus troughs and dose. Average dose-adjusted tacrolimus troughs and average tacrolimus total daily doses prior to and after rivaroxaban/apixaban initiation were compared. Subgroup analyses evaluating rivaroxaban and apixaban individually were performed. Rivaroxaban was prescribed to 18 recipients, and apixaban was prescribed to 32 recipients. Transplanted organs included kidney (n = 22), lung (n = 18), liver (n = 7), simultaneous pancreas and kidney (n = 1), and simultaneous kidney and liver (n = 2). The median doseadjusted tacrolimus trough and tacrolimus total daily dose prior to rivaroxaban/apixaban initiation was 2.15 ng/mL/mg (IQR 1.17, 3.37) and 4 mg (IQR 1.88, 6.25), respectively. The median dose-adjusted tacrolimus trough and tacrolimus total daily dose after rivaroxaban/apixaban initiation was 2.16 ng/mL/mg (IQR 1.24, 4.10) and 3.55 mg (IQR 1.5, 6.35), respectively. No significant difference was found between average dose-adjusted tacrolimus troughs or tacrolimus total daily doses before and after rivaroxaban/apixaban initiation or in the individual subgroup analyses for rivaroxaban/apixaban. It is unlikely that initiating rivaroxaban/apixaban affects tacrolimus troughs or requires tacrolimus dose adjustment. This study does not elucidate if tacrolimus affects rivaroxaban/apixaban pharmacokinetics or pharmacodynamics.

Keywords

solid organ transplant tacrolimus direct oral anticoagulants pharmacokinetics

Get full access to this article

View all access options for this article.

References

Sáez-Giménez

Berastegui

Loor

, et al. Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem. Transplant Rev (Orlando). 2015;29(2):85–92. doi:10.1016/j.trre.2014.12.005

Beckman

Hooper

Critchley

Ortel

. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 Suppl):S495–501. doi:10.1016/j.amepre.2009.12.017

Khan

Kalahasti

Rajagopal

, et al. Incidence of atrial fibrillation in heart transplant patients: long-term follow-up. J Cardiovasc Electrophysiol. 2006;17(8):827–831. doi:10.1111/j.1540-8167.2006.00497.x

Yerasi

Roy

Olson

, et al. Outcomes of lung transplant recipients with preoperative atrial fibrillation. Asian Cardiovasc Thorac Ann. 2018;26(2):127–132. doi:10.1177/0218492317754144

Saad

Elgendy

Mentias

, et al. Incidence, predictors, and outcomes of early atrial arrhythmias after lung transplant: a systematic review and meta-analysis. JACC Clin Electrophysiol. 2017;3(7):718–726. doi:10.1016/j.jacep.2016.12.009

Lentine

Schnitzler

Abbott

, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol. 2006;1(2):288–296. doi:10.2215/CJN.00920805

Nielsen

Bahnson

Davis

Palmer

. Atrial fibrillation after pulmonary transplant. Chest. 2004;126(2):496500. doi:10.1378/chest.126.2.496

Ortel

Neumann

Ageno

, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. doi:10.1182/bloodadvances.2020001831

Lip

GYH

Banerjee

Boriani

, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–1201. doi:10.1016/j.chest.2018.07.040

10.

January

Wann

Calkins

. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–132. doi:10.1016/j.jacc.2019.01.011

11.

Patel

Mahaffey

Garg

, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa1009638

12.

Granger

Alexander

McMurray

JJV

, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.

13.

Alsheikh

Alfayez

Al Yami

. Insights from practice with use of direct oral anticoagulants in transplantation. Prog Transplant. 2018;28(4):380–385. doi:10.1177/1526924818800056

14.

Bixby

Lichvar

Salerno

Park

. Use of direct-acting oral anticoagulants in solid organ transplantation: a systematic review. Pharmacotherapy. 2021;41(1):28–43. doi:10.1002/phar.2485

15.

Lichvar

Pierce

Salerno

Klem

Waldman

Park

. Utilization of direct-acting oral anticoagulation in solid organ transplant patients: a national survey of institutional practices. Clin Transplant. 2020;34(6):e13853. doi:10.1111/ctr.13853

16.

Lam

Bashir

Chaballa

Kraft

. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. Expert Rev Clin Pharmacol. 2019;12(8):781–790. doi:10.1080/17512433.2019.1637733

17.

de Jonge

Kuypers

DRJ

. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev (Orlando). 2008;22(1):6–20. doi:10.1016/j.trre.2007.09.002

18.

XARELTO (rivaroxaban) [package insert]. Janssen Pharmaceuticals, Inc; 2020.

19.

ELIQUIS (apixaban) [package insert]. Bristol-Myers Squibb Company and Pfizer Inc; 2019.

20.

Vanhove

Spriet

Annaert

, et al. Effect of the direct oral anticoagulants Rivaroxaban and Apixaban on the disposition of calcineurin inhibitors in transplant recipients. Ther Drug Monit. 2017;39(1):77–82. doi:10.1097/FTD.0000000000000356

21.

Pfrepper

Herber

Weimann

, et al. Safety and efficacy of direct oral anticoagulants under long-term immunosuppressive therapy after liver, kidney and pancreas transplantation. Transpl Int. 2021;34(3):423–435. doi:10.1111/tri.13804

22.

Bashir

Stickle

Chervoneva

Kraft

. Drug-drug interaction study of apixaban with cyclosporine and tacrolimus in healthy volunteers. Clin Transl Sci. 2018;11(6):590–596. doi:10.1111/cts.12580

23.

Ambrosi

Kreitmann

Cohen

Habib

Morange

. Anticoagulation with a new oral anticoagulant in heart transplant recipients. Int J Cardiol. 2013;168(4):4452–4453. doi:10.1016/j.ijcard.2013.06.148

24.

Barbarino

Staatz

Venkataramanan

Klein

Altman

. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563–585. doi:10.1097/FPC.0b013e328364db84

25.

Mehrotra

Rose

Pannu

Gill

Tonelli

Gill

. Incidence and consequences of acute kidney injury in kidney transplant recipients. Am J Kidney Dis. 2012;59(4):558–565. doi:10.1053/j.ajkd.2011.11.034

26.

Williams

Borges

Banh

, et al. Patterns of kidney injury in pediatric nonkidney solid organ transplant recipients. Am J Transplant. 2018;18(6):1481–1488. doi:10.1111/ajt.14638

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.31 MB